Skyhawk Therapeutics
Skyhawk Therapeutics Announces Agreement with Genentech
Skyhawk will use its SkySTARTM platform to develop drug candidates directed to multiple targets for oncology and neurodegenerative diseases. In exchange, Skyhawk will receive an upfront payment and may be eligible for more than $2 billion over time, including opt-in fees and milestone payments plus royalties on sales of commercialized medicines.
